Cerebras Systems (CBRS), the AI chip designer that went public last month on the NASDAQ, is sliding sharply after its first quarterly earnings report as a public company. Despite beating revenue estimates and narrowing its adjusted loss, the stock fell more than 17% on June 21 to $188.15, as investors focused on a coming compression in gross margins rather than the top-line beat.
At a Glance
- Price as of June 21, 2026: $188.15, down 17.12% on the day
- Market cap: $49.79 billion
- 52-week range: $185.22 to $386.34
- RSI: 34.06, approaching oversold territory
- No dividend reported
| Price | 188.15 USD |
|---|---|
| Day change | -38.81 (-17.12%) |
| 52-week range | 185.22 – 386.34 |
| Market cap | $49.79B |
| RSI (14) | 34.06 |
| Volume | 14,666,110 |
What Sent Cerebras Shares to a Post-IPO Low
Cerebras builds specialized processors designed to accelerate AI workloads at scale, competing in a segment of the semiconductor market where demand has been fierce and valuations extreme. The company only began trading last month, so Wednesday's session carries extra weight: at $188.15, shares are now just $2.93 above the IPO price of $185.00 and are sitting at the lowest level since the stock debuted.
The first quarterly report as a public company was not, on its face, a bad one. For the first quarter, Cerebras generated $193.4 million in revenue, roughly $10 million above the analyst consensus compiled by Visible Alpha. The adjusted loss came in at $2.48 million, narrower than what analysts had modeled. By most conventional measures, the company cleared the bar.
The problem is what comes next. Cerebras guided for adjusted gross margins of 36% to 38% in the current quarter, a meaningful step down from the 47% it posted in the first quarter. That roughly 10-percentage-point compression is what appears to be driving the selloff. Gross margin trajectory matters enormously for a loss-making chipmaker: it signals whether the path toward profitability is widening or narrowing, and right now the guidance says it is narrowing.
The daily decline of 17.12% comes on top of already significant losses from the post-IPO peak. Since the stock closed its first trading day, shares have fallen close to 40%. The 52-week high of $386.34 now looks distant, and at $188.15 the stock is near the low end of its entire trading history, with the 52-week floor sitting at $185.22.
Morgan Stanley Pushes Back on the Selloff
Not every analyst is reading the results through a bearish lens. Morgan Stanley analysts told clients in a note Wednesday that they remain bullish on Cerebras and raised their price target to $273 from $250, citing strong demand for the company's chips. The firm wrote that nothing in the first quarter numbers was disappointing and suggested the company may be taking a conservative posture with its outlook given that it is only navigating its first few quarters as a listed company.
That $273 target implies roughly 45% upside from the June 21 close, a gap that illustrates how sharply sentiment has diverged from at least one institutional view on the stock. Whether the margin guidance represents genuine structural pressure or deliberate conservatism is the central question the market is currently pricing.
What the Numbers Say
Valuation
With no P/E ratio available (the company is operating at an adjusted loss) and a market cap of $49.79 billion against first quarter revenue of $193.4 million, the implied annualized revenue run rate is roughly $775 million, putting the price-to-sales multiple at approximately 64 times. That is an extraordinarily high multiple even by AI semiconductor standards, and it assumes rapid revenue acceleration. There is no EPS figure in the traditional sense because the company remains loss-making on a reported basis, though the adjusted loss of $2.48 million in Q1 suggests the company is getting close to adjusted breakeven at the operating level.
Momentum and RSI
The RSI reading of 34.06 places Cerebras just above the conventional oversold threshold of 30. That level often attracts technical buyers who interpret it as a potential exhaustion point for selling pressure, but a stock can remain below 40 on the RSI for extended periods when the underlying concern is fundamental rather than purely sentiment driven. Given that the current quarter's margin guide is the stated catalyst for selling, any RSI-based bounce would likely be limited until the margin story clarifies.
Yield
Cerebras pays no dividend, which is consistent with its stage of development. Cash is being deployed toward growth and the path to sustained profitability, so yield is not a factor in how this stock is valued or traded.
Bull Case vs. Bear Case Risks
The bull case rests on demand. Morgan Stanley's note points to strong chip demand as the driver behind a raised price target, and the Q1 revenue beat supports that framing. If the 36% to 38% gross margin guide reflects conservatism from a management team unused to public company guidance cycles, then the actual results could surprise to the upside and the stock's proximity to its IPO price could look like a floor.
The bear case is that margin compression is real and structural. Moving from 47% gross margins to the mid-to-upper 30s in a single quarter is a significant shift, and if cost pressures are tied to supply chain, manufacturing, or competitive pricing dynamics, they may not reverse quickly. A stock trading at more than 60 times annualized revenue with no P/E ratio and decelerating margins is vulnerable to multiple compression even if revenue continues to grow.
Context: A Volatile Start to Public Life
Cerebras only began trading last month, so its entire price history as a public company fits inside the current 52-week range of $185.22 to $386.34. The distance between those two points, more than $200 per share, reflects how much volatility has characterized this name since its debut. The stock spent time near the top of that range before the margin warning pushed it toward the bottom.
At $188.15, the stock is approximately 4% above the IPO price of $185.00. That context matters: being above IPO price is technically positive, but the margin of safety is thin. A further modest decline on any additional negative news could push the stock below the price at which early institutional investors were allocated shares, a level that often attracts psychological attention from the market.
Frequently Asked Questions
Why did Cerebras stock fall if it beat earnings estimates?
The Q1 beat on revenue and the adjusted loss were offset by forward-looking guidance showing gross margins of 36% to 38% in the current quarter, down from 47% in Q1. Investors tend to price what is coming rather than what has passed, and the margin step-down raised concerns about near-term profitability progress.
What is the IPO price for Cerebras Systems?
Cerebras priced its IPO at $185.00 per share. As of June 21, 2026, the stock is trading at $188.15, approximately 4% above that level, after falling more than 17% on the day.
What did Morgan Stanley say about Cerebras after earnings?
Morgan Stanley raised its price target on Cerebras to $273 from $250 and maintained a bullish stance, writing that nothing in the Q1 numbers was disappointing. The firm suggested management may be providing conservative guidance as it adjusts to operating as a public company.
Is Cerebras Systems profitable?
On an adjusted basis, Cerebras posted a loss of $2.48 million in the first quarter of 2026, narrower than analyst forecasts. The company is not yet profitable on a reported basis, and no dividend is paid.
Where the Stock Goes From the IPO Price Floor
The key variable now is whether the second quarter gross margin comes in at the lower end or upper end of the 36% to 38% range guided, and whether that range proves conservative or accurate. Morgan Stanley's revised $273 target and the stock's current proximity to $185 IPO pricing define the near-term poles of investor expectation. The RSI at 34.06 reflects the accumulated selling pressure of the post-IPO decline, and the stock's next significant test will come when the current quarter's results allow the market to assess whether management's caution was warranted.
